![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vision OP China | LSE:VOC | London | Ordinary Share | GG00B28DJ748 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.115 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:0967N Vision Opportunity China Fund Ltd 01 February 2008 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, REPUBLIC OF SOUTH AFRICA OR JAPAN 1 February 2008 Vision Opportunity China Fund Limited Third Investment Vision Opportunity China Fund Limited ("VOC") (AIM:VOC.L) announces the completion of its third investment since listing on the AIM market ("AIM"). VOC has invested $2 million as part of a $25 million financing for China Sky One Medical, Inc., (OTCBB:CSKI), a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China. In return for its investment, VOC received the following: (a) 200,000 shares of common stock, and (b) 3 year warrants to purchase 60,000 shares of CSKI's common stock at an exercise price of $12.50 per share exercisable from July 2008. The closing price of OTCBB: CSKI's common stock on January 31, 2008 was $12.10. This transaction is described in more detail in the 8-K and other supporting documents filed by CSKI with the Securities and Exchange Commission. "The pharmaceutical industry in China has been experiencing exponential growth and we believe that this trend will continue in the foreseeable future. CSKI has a diverse product portfolio as well as an extensive sales and marketing team. With this financing and the intended acquisitions, the company will be able to leverage its platform to further expand and diversify its product portfolio and to capitalise on favorable market conditions and industry dynamics." stated Adam Benowitz, the portfolio manager of VOC at Vision Capital Advisors, LLC. Enquiries to: Vision Opportunity China Fund Limited David Benway, Director / Adam Benowitz, Portfolio Manager www.vocfund.com Tel: +1 (212) 849 8225 Fairfax I.S. PLC Paul Richards/ James King Tel: +44 (0) 20 7598 5368 Bankside Consultants Limited Simon Rothschild/Oliver Winters Tel: +44 (0) 20 7367 8888 NOTE TO EDITORS Vision Opportunity China Fund Limited Vision Opportunity China Fund Limited ("VOC") is a closed-ended listed fund traded on AIM. VOC primarily invests directly in listed companies with operations principally within Greater China. Greater China is a collective term for the territories administered by the People's Republic of China, those administered by the Republic of China and Singapore. China Sky One Medical, Inc. (CSKI) China Sky One Medical, Inc., a Nevada corporation, is a holding company whose principal operations are through its subsidiaries, which are engaged in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic kit products in China. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio-Engineering Company Limited ("First"), CSKI's principal revenue source is the manufacture and sale of over-the-counter pharmaceutical products. This information is provided by RNS The company news service from the London Stock Exchange END MSCILFVLFDILIIT
1 Year Vision OP China Chart |
1 Month Vision OP China Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions